Show simple item record

dc.contributor.authorDakterzada, Farida
dc.contributor.authorBenítez, Iván
dc.contributor.authorTarga, Adriano
dc.contributor.authorLladó, Albert
dc.contributor.authorTorres, Gerard
dc.contributor.authorRomero, Leila
dc.contributor.authorde Gonzalo Calvo, David
dc.contributor.authorMoncusí Moix, Anna
dc.contributor.authorTort Merino, Adrià
dc.contributor.authorHuerto Vilas, Raquel
dc.contributor.authorSánchez de la Torre, Manuel
dc.contributor.authorBarbé Illa, Ferran
dc.contributor.authorPiñol Ripoll, Gerard
dc.description.abstractBackground: Progressive cognitive decline is the most relevant clinical symptom of Alzheimer’s disease (AD). However, the rate of cognitive decline is highly variable between patients. Synaptic deficits are the neuropathological event most correlated with cognitive impairment in AD. Considering the important role of microRNAs (miRNAs) in regulating synaptic plasticity, our objective was to identify the plasma miRNAs associated with the rate of cognitive decline in patients with mild AD. Methods: We analyzed 754 plasma miRNAs from 19 women diagnosed with mild AD using TaqMan low-density array cards. The patients were grouped based on the rate of decline in the MMSE score after 2 years [<4 points (N = 11) and ≥4 points (N = 8)]. The differentially expressed miRNAs between the two groups were validated in an independent cohort of men and women (N = 53) with mild AD using RT-qPCR. Results: In the discovery cohort, 17 miRNAs were differentially expressed according to the fold change between patients with faster declines in cognition and those with slower declines. miR-342-5p demonstrated differential expression between the groups and a good correlation with the rate of cognitive decline in the validation cohort (r = −0.28; p = 0.026). This miRNA had a lower expression level in patients who suffered from more severe decline than in those who were cognitively more stable after 2 years (p = 0.049). Conclusion: Lower levels of miR-342-5p in plasma were associated with faster cognitive decline in patients with mild AD after 2 years of follow-up.ca_ES
dc.description.sponsorshipGeneralitat of Catalonia, Department of Health (PERIS 2019 SLT008/18/00050) and “Fundació La Marató TV3” (464/C/2014) to GP-R. IRBLleida is a CERCA Programme/Generalitat of Catalonia. FD was supported by Agency for Management of University and Research Grants and European Social Fund (FIB100153). AL received funding from Generalitat of Catalonia, Department of Health (PERIS 2016-2020 SLT008/18/00061) and Spanish Ministry of Science and Innovation – Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional (FEDER), European Union (“A way to build Europe”) (PI19/00449).ca_ES
dc.publisherFrontiers Mediaca_ES
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofFrontiers In Aging Neuroscience, 2021, vol. 13, p. 1-10ca_ES
dc.rightscc-by (c)authors, 2021ca_ES
dc.titleReduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimer’s Diseaseca_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by (c)authors, 2021
Except where otherwise noted, this item's license is described as cc-by (c)authors, 2021